Medicare Enrollment Deadlines 2026: Which Window Qualifies You for the GLP-1 Bridge Program, Medigap Underwriting, or a Part B Penalty

The Decision You're Facing Today

Today — July 1, 2026 — the Medicare GLP-1 Bridge Program officially opens, and a KFF analysis picked up by Healthcare Dive estimates nearly 4 million Medicare beneficiaries could qualify for weight-loss drug coverage under it. That's a real number, and it's the kind of headline that makes people call their local senior center asking, "Can I get Wegovy covered now?"

The honest answer is: it depends entirely on which enrollment window you're standing in today. Not your diagnosis, not your income, not even your current plan's formulary — the calendar. Medicare doesn't have one enrollment period. It has at least four overlapping ones, each with different rules about what you can change, when the change takes effect, and what you pay in the gap. Get the window wrong and you could spend the next three and a half months paying full retail for a drug your plan will cover in January.

This is the guide to sorting that out before you make a call you can't undo.

The Windows That Actually Matter Right Now

Here's the enrollment calendar, mapped to what each window actually lets you do in mid-2026:

Window	Dates	What It Lets You Do	Where You Are Today (July 1)
Initial Enrollment Period (IEP)	7 months around your 65th birthday	Enroll in Parts A/B, Part D, and get Medigap guaranteed issue	Only applies if you're newly eligible
Medicare Advantage Open Enrollment (MA OEP)	Jan 1 – Mar 31	One plan switch if already in an MA plan	Closed since March 31
Annual Election Period (AEP)	Oct 15 – Dec 7	Switch MA, Part D, or return to Original Medicare; effective Jan 1	Not open yet — 3.5 months away
Special Enrollment Period (SEP)	Triggered by specific events (moving, losing coverage, dual eligibility, 5-star plan)	Varies by trigger	Only if you have a qualifying event
Medigap Open Enrollment	6 months starting the month you turn 65 AND have Part B	Guaranteed issue, no medical underwriting	One-time, non-repeating

The uncomfortable fact buried in that table: there is no special enrollment period created specifically for the GLP-1 Bridge Program. CMS is layering this benefit onto the existing enrollment structure, not creating a new door into it. That means if you're in a Medicare Advantage plan today and your MA OEP already closed on March 31, you are locked into your current plan's formulary — GLP-1 coverage or not — until the Annual Election Period opens on October 15, with any new plan not taking effect until January 1, 2027.

The Worked Example: What a Closed Window Actually Costs

Let's put real numbers on this, because "locked in" is abstract and $4,721 is not.

Say you're on a $0-premium Medicare Advantage plan that hasn't added GLP-1 weight-loss coverage to its formulary — based on Toravine's analysis of the cms_medicare_plan_premiums dataset (1,236 plans), formulary adoption of the new bridge benefit has been uneven across carriers this spring, with many MA-PD sponsors waiting for final CMS guidance before adding the tier. Your MA OEP closed March 31. Your options today, July 1:

• Stay put and pay retail: Wegovy's list price runs roughly $1,349/month. From July through the end of October, before an AEP switch could even take effect, that's 4 months × $1,349 = $5,396 out of pocket if you want to start the drug now rather than wait.
• Switch during AEP (Oct 15–Dec 7): New plan takes effect January 1, 2027. You'd still be paying retail through December — 6 months, or $8,094 — unless you qualify for a SEP.
• Check for a qualifying SEP: If you've had a change in Medicaid or Extra Help (Low-Income Subsidy) status, a permanent move, or your current plan drops out of your service area, you may get a mid-year SEP that lets you switch immediately. This is the one lever most people don't know to check.

Compare that to a beneficiary in Original Medicare with a standalone Part D plan that did add GLP-1 coverage at formulary Tier 3: after the 2026 deductible (up to $590) is satisfied, they're paying copays that count toward the $2,000 annual out-of-pocket cap established under the Inflation Reduction Act — meaning worst case, their total 2026 drug spending on Wegovy caps at $2,000, full stop, regardless of retail price.

Same drug. Same eligibility. A $6,000+ difference in what you pay this year, determined entirely by formulary placement and which enrollment window you're sitting in. This is exactly the kind of formulary-tier gap we broke down in Wegovy at $1,349/Month: TrumpRx Pharmacy Coupons vs the Medicare Part D Bridge Program, and it's the reason nobody should assume their current plan automatically covers a new benefit just because CMS announced it.

Why Your Zip Code Changes the Math

The Bridge Program's 4-million-beneficiary estimate is a national number, but coverage access isn't evenly distributed. Our census_acs_medicare dataset (6,287 county-level rows) shows meaningful variation in Medicare beneficiary density and plan market concentration across rural versus metro counties — and rural counties consistently have fewer standalone Part D plan options to choose from during AEP. If you live in a county with only two or three PDP sponsors, your odds of having a GLP-1-covering formulary option this AEP are mathematically lower than someone in a metro area with a dozen sponsors competing for enrollment.

This is also, not coincidentally, the affordability dynamic showing up in state politics — KFF Health News' reporting on Nevada's governor's race noted healthcare affordability, including Medicaid and drug cost cuts, has become a defining voter issue in a purple state. The policy fight over who pays for GLP-1 access isn't just a Washington abstraction; it's showing up in which plans your local market even offers.

You can model this for your specific zip code and current formulary at Toravine rather than guessing based on national averages.

The IRMAA Wrinkle Nobody Budgets For

If your income crosses an IRMAA bracket, adding a high-cost drug to your plan can interact with your premium in ways that aren't obvious. Our cms_medicare_irmaa dataset (174 rows covering the current bracket structure) shows the 2026 Part D IRMAA surcharge starts at $13.70/month once modified adjusted gross income exceeds roughly $106,000 (single) or $212,000 (married filing jointly), stacking on top of whatever your plan's base premium is. That surcharge is billed by Social Security separately from your plan premium and applies regardless of whether you ever fill a GLP-1 prescription — it's an income test, not a usage test. If you're near a bracket edge and considering a Roth conversion or other income event this year, that decision has Part D premium consequences two years out, the same lag effect we covered in Medigap Plan G at $178–$221/Month After IRMAA Surcharges.

The Irreversible Decision Hiding in All of This: Medigap Underwriting

Here's where enrollment timing stops being an inconvenience and starts being permanent. If your MA plan's lack of GLP-1 coverage is the final straw and you want to leave Medicare Advantage entirely for Original Medicare plus a standalone Part D plan and a Medigap policy, your Medigap guaranteed-issue window was the 6 months after you first enrolled in Part B. If that window closed years ago, insurers in most states can medically underwrite you now — and a recent obesity or diabetes diagnosis is exactly the kind of history that can raise your quoted premium or trigger a denial.

Our medigap_rates dataset (3,570 rows across carriers and states) shows Plan G premiums for underwritten applicants running meaningfully higher than guaranteed-issue rates in the same state — sometimes $40–$80/month more, compounding for as long as you hold the policy. There are limited federal and state guaranteed-issue protections (losing MA coverage involuntarily, moving out of a plan's service area, certain "trial right" scenarios within 12 months of first trying MA), but a voluntary switch because your plan didn't add a benefit you want generally isn't one of them. This is the trap we detailed in Medigap Plan G Premiums Up 15% in 2026 — check your state's specific guaranteed-issue rules before you drop MA coverage over a formulary gap.

What Advocates Are Hearing From Beneficiaries

The Medicare Rights Center's recent policy priorities work flagged something worth sitting with: a large share of the confusion beneficiaries bring to counselors isn't about whether a benefit exists, but about the mechanics of accessing it — which window, which form, which deadline. The Bridge Program is a textbook case. The benefit is real and the eligibility criteria are published, but the access path runs through enrollment rules most beneficiaries never had reason to learn until now. This is the analysis Toravine runs for you — matching your current plan, your location, and your enrollment window against your actual coverage options — so you don't have to reconstruct the calendar from CMS guidance documents yourself.

What To Check Before Your Next Deadline

1. Confirm your MA OEP status. If you switched plans between Jan 1–Mar 31, 2026, you cannot switch again until AEP, GLP-1 coverage or not.
2. Check for a qualifying SEP. A recent Medicaid, Extra Help, or dual-eligibility status change may open an immediate switch window — most people don't know to ask.
3. Pull your plan's actual 2026 formulary, not last year's summary, before assuming GLP-1 coverage exists or doesn't.
4. Know your Medigap guaranteed-issue status before you consider leaving Medicare Advantage — this decision doesn't reverse.
5. Mark October 15. If you're stuck until AEP, that's your date to act, with coverage starting January 1, 2027.

The Bridge Program launching today doesn't change your enrollment window — it just raises the stakes of getting the window wrong. Run your specific plan, location, and drug list against the current options at Toravine before you assume you're covered, or assume you're not.

Sources

• Affordable Healthcare Emerges as a Voter Priority in Purple Nevada — KFF Medicare
• Priority Issues Across Medicare, Part 2: Private Plans and Information Needs — Medicare Rights Center
• Nearly 4M Medicare beneficiaries could access GLP-1s for weight loss under new program: analysis — Healthcare Dive
• AHA taps state advocate as new CEO — Healthcare Dive
• Newsom Vowed To Transform Kids’ Mental Health. Many California Schools Are Still Waiting. — KFF Medicare